Traduction de «risk among users of oral contraceptives » (Néerlandais → Français) :

(Hannaford 2007) Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College
(Hannaford 2007) Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users of oral contraceptives: cohort data from

Risk of venous thromboembolism in users of oral contraceptives containing
Risk of venous thromboembolism in users of oral contraceptives

(Margolis 2007) Margolis KL, Adami HO, Luo J et al. A prospective study of oral contraceptive use and risk of myocardial infarction among
(Margolis 2007) Margolis KL, Adami HO, Luo J et al. A prospective study of oral contraceptive use and risk of myocardial

Use of combined oral contraceptives among women with migraine and
Use of combined oral contraceptives among women with

(Chan 2004) Chan WS, Ray J, Wai EK et al. Risk of stroke in women exposed to low-dose oral contraceptives.
(CGESOC 2008) Collaborative Group on Epidemiological Studies of Ovarian Cancer.

(Jick 2006) Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or
(Jick 2006) Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing

Naar D.M. Grabrick et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.
D’après D.M. Grabrick et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.

Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing

Although oral administration of vancomycin was proven effective in terminating one MRSA outbreak in an ICU 54 it is generally unacceptable because of the risk of vancomycin resistance emerging among enterococci and S. aureus.
Bien qu’on ait démontré l’efficacité de l'administration par voie orale de vancomycine pour mettre un terme à une éclosion de MRSA dans un Intensive Care Unit 53 , elle est en général inacceptable en raison du risque d'apparition d’une résistance à la vancomycine parmi les entérocoques et S. aureus.